Results 91 to 100 of about 21,359 (272)

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum [PDF]

, 2011
BACKGROUND: Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced ...
Bjerregaard, Jon K, De Stricker, Karin, Gjerstorff, Morten F, Hansen, Tine P, Jensen, Helle A, Pfeiffer, Per, Schoennemann, Katrine R, Vestermark, Lene W   +7 more
core   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Clinical backgrounds and outcomes of patients with Barrett's esophageal adenocarcinoma treated via endoscopic submucosal dissection in Kyushu, Japan: A retrospective multicenter cohort study

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives Most esophageal cancers in Japan are squamous cell carcinomas; however, there has been some concern regarding a recent increase in Barrett's esophageal adenocarcinoma (BEA). This study aimed to clarify the clinical characteristics and outcomes of patients treated via endoscopic submucosal dissection (ESD) in Kyushu, including ...
Fumisato Sasaki, Kazuhiro Mizukami, Taro Akashi, Naoyuki Yamaguchi, Ryosuke Gushima, Hideaki Miyamoto, Shohei Uehara, Yoichiro Ono, Takashi Hisabe, Yuzuru Kinjo, Yuichiro Nasu, Kensuke Fukuda, Taisuke Inada, Yorinobu Sumida, Takashi Akutagawa, Tadashi Miike, Sho Suzuki, Hiroki Fukuya, Michita Mukasa, Mitsuru Esaki, Shinsuke Kumei, Yosuke Minoda, Tetsu Kinjo, Daisuke Yamaguchi, Yoshio Fukuda, Kazutoshi Hashiguchi, Hiroki Yano, Hiroshi Fujita, Ryo Shimoda, GI‐Kysuhu study group   +29 more
wiley   +1 more source

Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated Adenocarcinoma [PDF]

, 2014
Microsatellite instability (MSI) has been reported in various tumors, with colon cancer as the prototype. However, little is known about MSI in Barrett esophagus (BE)-associated adenocarcinoma.
Cohen, Cynthia, Demicco, Elizabeth G., Farris, Alton B., Finberg, Karin E., Fukuoka, Junya, Gaissert, Henning Arthur, Iafrate, Anthony John, Lauwers, Gregory Y., Le, Long Phi, Mandal, Rajni, Miller, Julie, Mino-Kenudson, Mari, Zukerberg, Lawrence R.   +12 more
core   +1 more source

A pilot study on anti‐reflux mucoplasty with valve as novel endoscopic therapy for gastroesophageal reflux disease

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Background and aims Endoscopic anti‐reflux therapies like anti‐reflux mucosectomy (ARMS) and anti‐reflux mucosal ablation have shown efficacy for gastroesophageal reflux disease (GERD) in systematic reviews and meta‐analyses. Anti‐reflux mucoplasty (ARM‐P), a refinement of ARMS, incorporates immediate closure of the resection site to reduce ...
Kazuki Yamamoto, Haruhiro Inoue, Ippei Tanaka, Rei Miyake, Masachika Saino, Kei Ushikubo, Miyuki Iwasaki, Yohei Nishikawa, Satoshi Abiko, Boldbaatar Gantuya, Manabu Onimaru, Mayo Tanabe   +11 more
wiley   +1 more source

Comparison of Outcomes of Totally Laparoscopic Total Gastrectomy (Overlap Reconstruction) versus Laparoscopic-Assisted Total Gastrectomy for Advanced Siewert III Esophagogastric Junction Cancer and Gastric Cancer of Upper and Middle Third of Stomach: Study Protocol for a Single-Center Randomized Controlled Trial

Cancer Management and Research, 2021
Juan Wang, Jun Yang, Xue Wen Yang, Xiao Hua Li, Jian Jun Yang, Gang Ji Department of Digestive Surgery, Xi Jing Hospital, The Fourth Military Medical University, Xi’an, People’s Republic of ChinaCorrespondence: Gang JiDepartment of Digestive ...
Wang J, Yang J, Yang XW, Li XH, Yang JJ, Ji G   +5 more
doaj  

Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study [PDF]

, 2017
Background: The optimal duration of firstline chemotherapy in metastatic esophagogastric cancer is unknown. In most clinical trials therapy was given until tumour progression or limiting toxicity.
Haag, Georg-Martin, Jäger, Dirk, Lordick, Florian, Quidde, Julia, Stocker, Gertraud   +4 more
core   +1 more source

Prevention of Adverse Events in Endoscopic Ultrasound‐Guided Biliary Drainage

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Endoscopic ultrasound‐guided biliary drainage (EUS‐BD) is used when biliary drainage using endoscopic retrograde cholangiopancreatography fails. Recently, it has been adopted as a primary biliary drainage method, and its indications have expanded.
Hirotoshi Ishiwatari, Hiroki Sakamoto, Takuya Doi, Masahiro Yamamura   +3 more
wiley   +1 more source

Application of preoperative endoscopic ultrasonography-guided carbon nanoparticle tattooing combined with titanium clip labeling in esophagogastric junction adenocarcinoma

The Turkish Journal of Gastroenterology, 2019
Cite this article as: Lin L, Wang M, Hong J, Yang S, Wang Y. Application of preoperative endoscopic ultrasonography-guided carbon nanoparticle tattooing combined with titanium clip labeling in esophagogastric junction adenocarcinoma. Turk J Gastroenterol
Lan Lin, Ming Wang, Jie Hong, Sheng Yang, Yu Wang   +4 more
doaj   +1 more source

Therapeutic approaches to gastroesophageal junction adenocarcinomas [PDF]

, 2014
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/108681/1/nyas12532 ...
Agrawal, Aloia, Apisarnthanarax, Ayyappan, Baardwijk, Bang, Barbour, Bettstetter, Blom, Bogush, Bogush, Bruzzi, Brücher, Brücher, Brücher, Brücher, Cerfolio, Chang, Chirieac, Cunningham, Dikken, Dulak, Eto, Farris, Gonzalez, Griffin, Gurland, Hagen, Heijl, Heijl, Illig, Kwee, Lambrecht, Langer, Langer, Loon, Mandard, Mann, Marsman, Medical Research Council Oesophageal Cancer Working Group, Miller, Moertel, Peyre, Peyre, Ronellenfitsch, Rossum, Sarkaria, Schneider, Shapiro, Siewert, Sjoquist, Smit, Stahl, Swisher, Swisher, Takebayashi, Tepper, Therasse, Walsh, Westerterp, Xie   +60 more
core   +1 more source